We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
Medtronic (MDT - Free Report) closed the most recent trading day at $81.90, moving -1.23% from the previous trading session. This change lagged the S&P 500's 0.49% loss on the day. Elsewhere, the Dow saw a downswing of 0.05%, while the tech-heavy Nasdaq depreciated by 0.9%.
Shares of the medical device company witnessed a loss of 3.29% over the previous month, trailing the performance of the Medical sector with its loss of 0.86%, and the S&P 500's gain of 12.8%.
Analysts and investors alike will be keeping a close eye on the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to go public on June 3, 2026. The company's upcoming EPS is projected at $1.58, signifying a 2.47% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $9.66 billion, up 8.22% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.57 per share and a revenue of $36.15 billion, representing changes of +1.46% and +7.78%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Medtronic. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.87% lower within the past month. Currently, Medtronic is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 14.89. This expresses a discount compared to the average Forward P/E of 19.05 of its industry.
We can also see that MDT currently has a PEG ratio of 2.15. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 1.55 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
Medtronic (MDT - Free Report) closed the most recent trading day at $81.90, moving -1.23% from the previous trading session. This change lagged the S&P 500's 0.49% loss on the day. Elsewhere, the Dow saw a downswing of 0.05%, while the tech-heavy Nasdaq depreciated by 0.9%.
Shares of the medical device company witnessed a loss of 3.29% over the previous month, trailing the performance of the Medical sector with its loss of 0.86%, and the S&P 500's gain of 12.8%.
Analysts and investors alike will be keeping a close eye on the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to go public on June 3, 2026. The company's upcoming EPS is projected at $1.58, signifying a 2.47% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $9.66 billion, up 8.22% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.57 per share and a revenue of $36.15 billion, representing changes of +1.46% and +7.78%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Medtronic. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.87% lower within the past month. Currently, Medtronic is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 14.89. This expresses a discount compared to the average Forward P/E of 19.05 of its industry.
We can also see that MDT currently has a PEG ratio of 2.15. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 1.55 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.